CDClare Diester

Clare Diester

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Clare Diester has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Wake-activated neuronal populations that regulate sleep drive

    by William Joo, Clare Diester, Vassilis Bitsikas, Myrto Panopoulou, Amelia Hidalgo, Konstantinos Ntemos, Rodrigo C. G. Pena, Fabia Imhof, Iris Odstrcil, Flavio Donato, et al.

    Prolonged wakefulness increases sleep drive and is normally compensated for by increased sleep 1–3 . This homeostatic regulation of sleep shapes our lives profoundly, but the underlying neural circuit mechanisms remain poorly understood. Here, we identify wake-activated neurons that regulate sleep drive in mice, using whole-brain activity mapping, targeted neuronal manipulations and electrophysiology. By comparing whole-brain responses to sleep deprivation, recovery sleep and circadian behaviour, we identify the anterior medial preoptic area and the median raphe as candidate regions that encode sleep deficit. Activating sleep-deprivation-responsive cells in these regions induces increases in sleep duration and intensity that resemble recovery sleep. Conversely, inhibiting deprivation-responsive cells reduces sleep and abolishes the increased sleep propensity usually observed during deprivation. Neurons in the median raphe that are responsive to sleep deprivation project to subcortical sleep-associated regions and act through the preoptic hypothalamus. These deprivation-sensitive cells include serotonergic neurons and a distinct population of GABAergic neurons, whose intrinsic excitability increases during sleep deprivation. Co-activation of GABAergic and serotonergic neurons synergistically promotes sleep, whereas co-inhibition chronically decreases sleep by nearly 70%. Remarkably, most mice survive despite this marked reduction in sleep, without the compensatory increases in sleep drive or the behavioural deficits typically associated with severe sleep deprivation. Together, these results define neuronal populations that are activated during wakefulness and are crucial for sleep drive.


  • Open Access

    At the Intersection of Pain and Sleep: a Roadmap for Preclinical Pain Research

    by Clare M. Diester, William Joo

    The complex relationship between pain and sleep has received increasing attention for its therapeutic potential. Over half of chronic pain patients suffer from sleep disorders, and poor sleep is a strong predictor for pain in clinical populations. Understanding the bidirectional relationship between pain and sleep is crucial for developing improved clinical treatment strategies. This review provides (1) a primer on preclinical methods used to measure sleep behaviors, (2) an overview of neural circuits at the intersection of pain and sleep, and (3) considerations for future pain and sleep investigations and treatment strategies.


  • Effects of Repeated Treatment with the Monoacylglycerol Lipase Inhibitor MJN110 on Pain-Related Depression of Nesting and Cannabinoid 1 Receptor Function in Male and Female Mice

    by Clare M. Diester, Hallie Balint, James C. Gillespie, Aron H. Lichtman, Laura J. Sim-Selley, Dana E. Selley, S. Stevens Negus

    MJN110 inhibits the enzyme monoacylglycerol lipase (MAGL) to increase levels of the endocannabinoid (eCB) 2-arachidonoylglycerol (2-AG), an endogenous high-efficacy agonist of cannabinoid 1 and 2 receptors (CB1/2R). MAGL inhibitors are under consideration as candidate analgesics, and we reported previously that acute MJN110 produced partial antinociception in an assay of pain-related behavioral depression in mice. Given the need for repeated analgesic administration in many pain patients and the potential for analgesic tolerance during repeated treatment, this study examined antinociceptive effects of repeated MJN110 on pain-related behavioral depression and CB1R-mediated G-protein function. Male and female ICR mice were treated daily for 7 days in a 2x2 design with (a) 1.0 mg/kg/day MJN110or its vehicle followed by (b) intraperitoneal injection of dilute lactic acid (IP acid) or its vehicle as a visceral noxious stimulus to depress nesting behavior. After behavioral testing, G-protein activity was assessed in lumbar spinal cord andfive brain regions using an assay of CP55,940-stimulated [35S]GTPɣS activation. As reported previously, acute MJN110 produced partial but significant relief of IP acid-induced nesting depression on Day 1. After 7 days, MJN110 continued to produce significant but partial antinociception in males, while antinociceptive tolerance developed in females. Repeated MJN110 also produced modest decreases in maximum levels of CP55,940-induced [35S]GTPɣS binding in spinal cord and most brain regions. These results indicate that repeated treatment with a relatively low antinociceptive MJN110 dose produces only partial and sex-dependent transient antinociception associated with the emergence of CB1R desensitization in this model of IP acid-induced nesting depression. Significance Statement The drug MJN110 inhibits monoacylglycerol lipase (MAGL) to increase levels of the endogenous cannabinoid 2-arachidonoylglycerol and produce potentially useful therapeutic effects including analgesia. This study used an assay of pain-related behavioral depression in mice to show that repeated MJN110 treatment produced (1) weak but sustained antinociception in male mice, (2) antinociceptive tolerance in females, and (3) modest cannabinoid-receptor desensitization that varied by region and sex. Antinociceptive tolerance may limit the utility of MJN110 for treatment of pain.


  • Open Access

    Assessment of Monoacyglycerol Lipase Inhibition for Acute and Chronic Antinociception in a Behavioral Battery for Testing Candidate Analgesics in Mice

    by Clare Diester, Aron Lichtman, S. Negus

    Objective and Hypothesis: There is a pressing need for discovery of novel, safe, and effective analgesics with improved preclinical‐to‐clinical translation. This study addressed these issues by evaluating the antinociceptive effectiveness of the monoacylglycerol lipase (MAGL)‐selective inhibitors MJN110 and JZL184 in a battery of pain‐stimulated, pain‐depressed, and pain‐independent behaviors in male and female mice. Ketoprofen (cyclooxygenase 1/2 inhibitor) was used as a clinically‐effective analgesic positive control, and ∆9‐tetrahydrocannabinol (THC; cannabinoid 1/2 receptor (CB 1/2­ R) agonist) as a negative control that is not clinically effective to treat acute pain. We hypothesized that ketoprofen and MAGL‐selective inhibitors would produce antinociception on endpoints of pain‐stimulated and pain‐depressed behaviors at doses that did not alter pain‐independent behaviors, whereas THC would not. Methods: Intraperitoneal dilute lactic acid (IP acid) served as an acute noxious stimulus in male and female ICR mice to produce two IP acid‐stimulated behaviors (stretching and facial grimace) and two IP acid‐depressed behaviors (rearing and nesting). Pain‐independent drug effects were assessed in nesting and locomotion in the absence of IP acid. All test drugs were delivered subcutaneously and evaluated for effectiveness to alleviate pain‐related behaviors at doses below those that altered pain‐independent behaviors. The assay of IP acid‐depressed nesting was also used to assess MJN110 time course, sensitivity to blockade by the CB 1 R‐ and CB 2 R‐selective antagonists rimonabant and SR144528, and effects of repeated dosing for 7 consecutive days. Results and Significance: Ketoprofen (0.1‐10 mg/kg) produced robust antinociception without general behavioral disruption on all IP acid‐stimulated and IP acid‐depressed behaviors. MJN110 (0.1‐3.2 mg/kg) and JZL184 (1.0‐32 mg/kg) produced antinociception without motor disruption on endpoints of stretching (MJN110 only), grimace, and nesting, but not rearing. THC (1‐10 mg/kg) attenuated IP acid‐stimulated stretching and facial grimace at doses that did not produce general motor disruption; however, THC did not alleviate IP acid‐induced depression of either nesting or rearing. MJN110 (1.0 mg/kg) antinociception in the assay of IP acid‐induced nesting depression showed a long duration (40min – 6hr) mediated by CB 1 R but not CB 2 R and tended to be stronger in females. Chronic MJN110 (1.0 mg/kg/day × 7 days) showed sex‐dependent antinociception and tolerance, with females showing tolerance by Day 7 and males showing no significant antinociceptive effect across all 7 days. These results provide modest support for further consideration of MAGL‐selective inhibitors, especially MJN110, as candidate analgesics, with future work needed to assess sex‐dependent effects. However, it should be noted that none of the cannabinoids were as effective in this behavioral battery as ketoprofen.